Protocol Ledger

NCT06413654 · Phase II/III · RECRUITING

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Interventional Phase II/III clinical trial protocol NCT06413654 sponsored by Shanghai Jiaolian Drug Research and Development Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-17 Enrollment: 132 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06413654
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)132 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06413654
Protocol FieldVerified Registry Value
NCT IdentifierNCT06413654
Consolidated Lead SponsorShanghai Jiaolian Drug Research and Development Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment132 participants (ESTIMATED)
Registered Start Date2024-07-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI